Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
288 hedge funds and large institutions have $6.12B invested in Blueprint Medicines in 2021 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 99 increasing their positions, 94 reducing their positions, and 29 closing their positions.
95% more call options, than puts
Call options by funds: $36.7M | Put options by funds: $18.9M
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
38% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 29
19% more capital invested
Capital invested by funds: $5.14B → $6.12B (+$981M)
2% more funds holding
Funds holding: 281 → 288 (+7)
1.59% more ownership
Funds ownership: 100.24% → 101.83% (+1.6%)
5% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 94
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$110M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
+$63.4M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$39.6M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$36M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
+$29.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$96.7M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$55.9M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$48.5M |
| 4 |
Morgan Stanley
New York
|
-$37.3M |
| 5 |
CCM
Cadian Capital Management
New York
|
-$25.1M |
BPMC Hedge Fund Activity: Q3 2021 in Review
288 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2021, worth a combined $6.12B — up 19% from $5.14B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new BPMC positions and 29 closed out — a net gain of 11 holders — while 99 added to existing stakes and 94 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $110M. The largest seller was Fidelity Investments, cutting an estimated $96.7M.
- 288 institutional investors held Blueprint Medicines (BPMC) as of Q3 2021, up from 281 in Q2 2021.
- Funds reported $6.12B of Blueprint Medicines stock for Q3 2021, up 19% quarter-over-quarter.
- 40 funds opened new Blueprint Medicines positions in Q3 2021 and 29 closed out, a net change of +11 holders.
- The largest Blueprint Medicines buyer in Q3 2021 was Wellington Management Group, an estimated $110M added.
- The largest Blueprint Medicines seller in Q3 2021 was Fidelity Investments, an estimated $96.7M sold.
Based on aggregated 13F filings for Q3 2021.